Lyell Immunopharma, Inc. (LYEL)

NASDAQ: LYEL · Real-Time Price · USD

13.17

+0.20 (1.54%)

Jul 30, 2026, 1:24 PM EDT - Market open

Lyell Immunopharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-246.41	-274.45	-342.99	-234.63	-183.12	-250.22
Depreciation & Amortization	10.43	11.54	19.63	20.25	18.02	13.62
Stock-Based Compensation	40.1	41.83	33.14	47.08	81.92	62.2
Other Adjustments	-5.9	80.95	130.95	0.18	-4.37	44.13
Changes in Accounts Payable	1.7	-2.34	-3.23	1.46	0.67	0.09
Changes in Accrued Expenses	-1.42	-7.64	-1.25	-0.72	-0.46	4.54
Changes in Unearned Revenue	-	-	-	-	-84.65	-10.51
Changes in Other Operating Activities	-1.7	0.09	1.36	2.68	2.43	9.89
Operating Cash Flow	-133.8	-150.02	-162.39	-163.69	-169.56	-126.25
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Capital Expenditures	-0.62	-0.78	-0.46	-2.69	-24.28	-65.5
Sale of Property, Plant & Equipment	-	0.29	-	-	-	-
Purchases of Investments	-231.67	-278.9	-394.71	-476.88	-406.32	-673.47
Proceeds from Sale of Investments	275.21	374.68	548.94	663.61	419.05	617.4
Cash Acquisitions	-	-41.2	-31.35	-	-	-
Investing Cash Flow	2.01	54.1	122.42	184.05	-11.54	-121.57

Financing Activities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Issuance of Common Stock	1.7	50.41	1.4	2.2	11.1	401.24
Repurchase of Common Stock	-0	-0	-0.08	-0.46	-0.46	-
Net Common Stock Issued (Repurchased)	1.69	50.41	1.33	1.74	10.64	401.24
Financing Cash Flow	102.13	50.41	1.33	1.74	10.64	401.24

Net Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Cash Flow	-29.66	-45.52	-38.64	22.1	-170.46	153.42

Free Cash Flow

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-134.42	-150.8	-162.86	-166.38	-193.83	-191.75
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-433610.00%	-418900.00%	-266980.00%	-127985.00%	-228.89%	-1800.50%
Free Cash Flow Per Share	-7.13	-8.82	-12.46	-13.26	-15.69	-28.22
Levered Free Cash Flow	-238.02	-273.58	-326.95	-213.65	-271.39	-298.08
Unlevered Free Cash Flow	-247.92	-268.54	-342.71	-226.02	-275.33	-262.64

SEC Filings: 10-K · 10-Q